Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Lanthier

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Journal Des Maladies Vasculaires|December 15, 2010
[Evaluation of thromboprophylaxis in patients hospitalized in a tertiary care center: an applicable model of clinical practice evaluation. Revision of 320 cases]L Lanthier, D Béchard, D Viens, et al.
The Journal of Laryngology and Otology|April 1, 1984
Bromocriptine-associated ototoxicityP L Lanthier, M Y Morgan, J Ballantyne
La Revue De Medecine Interne|June 20, 2021
[In patients hospitalized for COVID-19 with hypoxia and systemic inflammation, does tocilizumab reduce 28-days mortality compared to standard treatment, and is it safe?]L Lanthier, M Mayette, M-É Plourde, et al.
La Revue De Medecine Interne|February 22, 2021
[In subjects 16 years of age and older, is messenger RNA vaccine BNT162b2 against COVID-19 effective and safe?]L Lanthier, A Carignan, M-É Plourde, et al.
La Revue De Medecine Interne|December 9, 2019
[In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?]L Lanthier, G Huard, M-É Plourde, et al.
Clinical Pharmacology and Therapeutics|June 18, 2019
An Analysis of Follow-On Development in New Drug Classes, January 1986-June 2018Michael L Lanthier, Kirk W Kerr, Kathleen L Miller
La Revue De Medecine Interne|August 17, 2020
[In patient with symptomatic peripheral arterial disease who had undergone lower-extremity revascularization, does rivaroxaban 2.5 mg twice daily plus aspirin reduce the composite risk of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke or cardiovascular death compared to aspirin alone while being safe?]L Lanthier, G Huard, M-E Plourde, et al.
La Revue De Medecine Interne|December 23, 2023
[In a patient undergoing mechanical ventilation for at least 3 days, does a 3-day course of inhaled amikacin reduce the incidence of ventilator-associated pneumonia compared to placebo, and is it safe?]L Lanthier, M Mayette, M-É Plourde, et al.
La Revue De Medecine Interne|January 11, 2022
[In hypertensive patients aged 60 to 80 years, does more intensive antihypertensive treatment reduce cardiovascular events compared to standard treatment while being safe?]L Lanthier, D Lauzon, M-É Plourde, et al.
La Revue De Medecine Interne|November 28, 2022
[In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve and maintain good glycemic control?]L Lanthier, A Mutchmore, M-É Plourde, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Journal Des Maladies Vasculaires|December 15, 2010
[Evaluation of thromboprophylaxis in patients hospitalized in a tertiary care center: an applicable model of clinical practice evaluation. Revision of 320 cases]L Lanthier, D Béchard, D Viens, et al.
The Journal of Laryngology and Otology|April 1, 1984
Bromocriptine-associated ototoxicityP L Lanthier, M Y Morgan, J Ballantyne
La Revue De Medecine Interne|June 20, 2021
[In patients hospitalized for COVID-19 with hypoxia and systemic inflammation, does tocilizumab reduce 28-days mortality compared to standard treatment, and is it safe?]L Lanthier, M Mayette, M-É Plourde, et al.
La Revue De Medecine Interne|February 22, 2021
[In subjects 16 years of age and older, is messenger RNA vaccine BNT162b2 against COVID-19 effective and safe?]L Lanthier, A Carignan, M-É Plourde, et al.
La Revue De Medecine Interne|December 9, 2019
[In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?]L Lanthier, G Huard, M-É Plourde, et al.
Clinical Pharmacology and Therapeutics|June 18, 2019
An Analysis of Follow-On Development in New Drug Classes, January 1986-June 2018Michael L Lanthier, Kirk W Kerr, Kathleen L Miller
La Revue De Medecine Interne|August 17, 2020
[In patient with symptomatic peripheral arterial disease who had undergone lower-extremity revascularization, does rivaroxaban 2.5 mg twice daily plus aspirin reduce the composite risk of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke or cardiovascular death compared to aspirin alone while being safe?]L Lanthier, G Huard, M-E Plourde, et al.
La Revue De Medecine Interne|December 23, 2023
[In a patient undergoing mechanical ventilation for at least 3 days, does a 3-day course of inhaled amikacin reduce the incidence of ventilator-associated pneumonia compared to placebo, and is it safe?]L Lanthier, M Mayette, M-É Plourde, et al.
La Revue De Medecine Interne|January 11, 2022
[In hypertensive patients aged 60 to 80 years, does more intensive antihypertensive treatment reduce cardiovascular events compared to standard treatment while being safe?]L Lanthier, D Lauzon, M-É Plourde, et al.
La Revue De Medecine Interne|November 28, 2022
[In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve and maintain good glycemic control?]L Lanthier, A Mutchmore, M-É Plourde, et al.
Pageof 5